Research report: PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
A small, single-arm phase II study found a 56.3% response rate with first-line cadonilimab plus PF chemotherapy in 16 patients ...
